2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, January 16, 2023
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Hidradenitis suppurativa, National Organization for Rare Disorders, Crohn's disease, Groin, Dermis, Epidemiology, Sarcoidosis, Skin, National Organ Transplant Act of 1984, Scar, CD, Squamous cell carcinoma, Diagnosis, Patient, Abscess, Organizing, Biopsy, Health Data Insight, Hidradenitis, Fibrosis, Vaccine, Renewable energy, Dietary supplement, Animal, Medicine, Pharmaceutical industry, HS
Geotags: 
EUROPE, UNITED KINGDOM, UNITED STATES, FRANCE, ITALY, GERMANY, SPAIN, JAPAN
Organisation: 
RESEARCH AND MARKETS
Summary
Key Points: 
  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.


The "Hidradenitis Suppurativa (HS) - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • The EU-5
  • Japan

Study Period: 2019-2032

Hidradenitis Suppurativa Disease Understanding

Hidradenitis Suppurativa Overview

According to the National Organization of Rare Disorders, hidradenitis Suppurativa is a chronic condition characterized by swollen, painful lesions, occurring in the armpit, groin, anal and breast regions. It is painful and long-term skin condition causing abscesses and scarring on the skin.

Affected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. Although foreign body type granulomas are a common finding in HS, the presence of discrete epithelioid granulomas in the dermis away from the site of active inflammation is unusual and should alert the pathologist to the possibility of a systemic granulomatous disease like Crohn's disease (CD) or sarcoidosis.

The longstanding disease can result in fibrosis, dermal contractures, significant scarring, the formation of fistulae, and rarely malignant transformation to squamous cell carcinoma.

The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists, and biopsy is rarely required, especially in well-developed lesions.

Hidradenitis Suppurativa Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of Hidradenitis Suppurativa, gender-specific prevalent population of Hidradenitis Suppurativa, age-specific prevalent population of Hidradenitis Suppurativa, stage-specific population of Hidradenitis Suppurativa, in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the Hidradenitis Suppurativa epidemiology in the 7MM

Country Wise- Hidradenitis Suppurativa Epidemiology

  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The total diagnosed prevalent population of Hidradenitis Suppurativa in the 7MM comprised of 1,239,695 cases in 2021 and are projected to increase during the forecast period.
  • The total diagnosed prevalent population of Hidradenitis Suppurativa in the United States is 572,057 in 2021.
  • The United States contributed to the largest prevalent population of Hidradenitis Suppurativa, in 7MM in 2021.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the total diagnosed prevalent population of Hidradenitis Suppurativa was 89,917 in 2021 and is anticipated to rise during the forecast period.
  • In 2021, males and females accounted for 143,014 and 429,043 cases respectively in the United States.

Scope of the Report

  • The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
  • Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment.
  • The report provides insight about the historical and forecasted patient pool of Hidradenitis Suppurativa in seven major markets covering the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding epidemiological trends.

Key Questions

  • What is the disease risk, burden and unmet needs of Hidradenitis Suppurativa?
  • What is the historical Hidradenitis Suppurativa patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Hidradenitis Suppurativa at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Hidradenitis Suppurativa during the study period (2019-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa.
  • To understand the future market competition in the Hidradenitis Suppurativa market and Insightful review of the key market drivers and barriers.
  • Quantify patient populations in the global Hidradenitis Suppurativa market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

For more information about this report visit https://www.researchandmarkets.com/r/d3a86o

Copyright: 
Copyright Business Wire 2023